CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Telehealth-delivered Supervised Consumption Services: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: August 31, 2020
Project Number: RA1131-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of telehealth-delivered supervised consumption services for individuals who consume illicit drugs?
  2. What is the cost-effectiveness of telehealth-delivered supervised consumption services for individuals who consume illicit drugs?
  3. What are the evidence-based guidelines regarding the use of supervised consumption services for individuals who consume illicit drugs?

Key Message

One evidence-based guideline was identified regarding the use of supervised consumption services for individuals who consume illicit drugs. No relevant literature was identified regarding the clinical or cost-effectiveness of telehealth-delivered supervised consumption services for individuals who consume illicit drugs.